PRL-3 activates NF-κB signaling pathway by interacting with RAP1

Biochemical and Biophysical Research Communications

Volumn 430, Issue 1, 2013, Pages 196-201

  Lian, Shenyi ^a   Meng, Lin ^a   Liu, Caiyun ^a   Xing, Xiaofang ^a   Song, Qian ^a   Dong, Bin ^a   Han, Yong ^a   Yang, Yongyong ^a   Peng, Lirong ^b   Qu, Like ^a   Shou, Chengchao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; NF B; PRL 3; PTP; RAP1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATASE; PHOSPHATASE OF REGENERATING LIVER 3; RAP1 PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOSOL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CYTOSOL; GENE EXPRESSION REGULATION; HUMANS; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; TELOMERE-BINDING PROTEINS; TRANSCRIPTION FACTOR RELA;

EID: 84872377523     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.11.036     Document Type: Article

References (30)

1. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Biol. 2006, 7:833-846.
2. Zeng Q., Dong J.M., Guo K., Li J., Tan H.X., Koh V., Pallen C.J., Manser E., Hong W. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 2003, 63:2716-2722.
3. Li J., Guo K., Koh V.W., Tang J.P., Gan B.Q., Shi H., Li H.X., Zeng Q. Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin. Cancer Res. 2005, 11:2195-2204.
4. Stephens B.J., Han H., Gokhale V., Von Hoff D.D. PRL phosphatases as potential molecular targets in cancer. Mol. Cancer Ther. 2005, 4:1653-1661.
5. Saha S., Bardelli A., Buckhaults P., Velculescu V.E., Rago C., St C.B., Romans K.E., Choti M.A., Lengauer C., Kinzler K.W., Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science 2001, 294:1343-1346.
6. Peng L., Ning J., Meng L., Shou C. The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J. Cancer Res. Clin. Oncol. 2004, 130:521-526.
7. Li Z., Zhan W., Wang Z., Zhu B., He Y., Peng J., Cai S., Ma J. Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem. Biophys. Res. Commun. 2006, 348:229-237.
8. Xing X., Peng L., Qu L., Ren T., Dong B., Su X., Shou C. Prognostic value of PRL-3 overexpression in early stages of colonic cancer. Histopathology 2009, 54:309-318.
9. Guo K., Li J., Tang J.P., Koh V., Gan B.Q., Zeng Q. Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer. Biol. Ther. 2004, 3:945-951.
10. Song R., Qian F., Li Y.P., Sheng X., Cao S.X., Xu Q. Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo. PLoS One 2009, 4:e4450.
11. Fiordalisi J.J., Keller P.J., Cox A.D. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 2006, 66:3153-3161.
12. Peng L., Xing X., Li W., Qu L., Meng L., Lian S., Jiang B., Wu J., Shou C. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol. Cancer 2009, 8:110-122.
13. Liang F., Luo Y., Dong Y., Walls C.D., Liang J., Jiang H.Y., Sanford J.R., Wek R.C., Zhang Z.Y. Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase. J. Biol. Chem. 2008, 283:10339-10346.
14. Wang H., Quah S.Y., Dong J.M., Manser E., Tang J.P., Zeng Q. PRL3 down regulates PTEN expression and signals through PI3K promote epithelial-mesenchymal transition. Cancer Res. 2007, 67:2922-2926.
15. Lempiainen H., Halazonetis T.D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009, 28:3067-3073.
16. Zhou J., Bi C., Chng W.J., Cheong L.L., Liu S.C., Mahara S., Tay K.G., Zeng Q., Li J., Guo K., Tan C.P., Yu H., Albert D.H., Chen C.S. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One 2011, 6:e19798.
17. Min S.H., Kim D.M., Heo Y.S., Kim H.M., Kim I.C., Yoo O.J. Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2. Life Sci. 2010, 86:66-72.
18. Basak S., Jacobs S.B., Krieg A.J., Pathak N., Zeng Q., Kaldis P., Giaccia A.J., Attardi L.D. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol. Cell 2008, 30:303-314.
19. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19:2100-2110.
20. Li B., Oestreich S., de Lange T. Identification of human Rap1: implications for telomere evolution. Cell 2000, 101:471-483.
21. O'Connor M.S., Safari A., Liu D., Qin J., Zhou S. The human Rap1 protein complex and modulation of telomere length. J. Biol. Chem. 2004, 279:28585-28591.
22. Sfeir A., Kabir S., van Overbeek M., Celli G.B., de Lange T. Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science 2010, 327:1657-1661.
23. Martinez P., Thanasoula M., Carlos A.R., Gomez-Lopez G., Tejera A.M., Schoeftner S., Dominguez O., Pisano D.G., Tarsounas M., Blasco M.A. Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nat. Cell Biol. 2010, 12:768-780.
24. Teo H., Ghosh S., Luesch H., Ghosh A., Wong E.T., Malik N., Orth A., de Jesus P., Perry A.S., Oliver J.D., Tran N.L., Speiser L.J., Wong M., Saez E., Schultz P., Chanda S.K., Verma I.M., Tergaonkar V. Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat. Cell Biol. 2010, 12:758-767.
25. Guo K., Li J., Wang H., Osato M., Tang J.P., Quah S.Y., Gan B.Q., Zeng Q. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res. 2006, 66:9625-9635.
26. Fagerli U.M., Holt R.U., Holien T., Vaatsveen T.K., Zhan F., Egeberg K.W., Barlogie B., Waage A., Aarset H., Dai H.Y., Shaughnessy J.J., Sundan A., Borset M. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 2008, 111:806-815.
27. Karin M., Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
28. Naugler W.E., Karin M. NF-κB and cancer - identifying targets and mechanisms. Curr. Opin. Genet. Dev. 2008, 18:19-26.
29. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 2001, 107:135-142.
30. Bae N.S., Baumann P. A RAP1/TRF2 complex inhibits nonhomologous end-joining at human telomeric DNA ends. Mol. Cell 2007, 26:323-334.